• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.

作者信息

Mamounas Eleftherios P, Lembersky Barry, Jeong Jong-Hyeon, Cronin Walter, Harkins Barbara, Geyer Charles, Wickerham Donald Lawrence, Paik Soonmyung, Costantino Joseph, Wolmark Norman

机构信息

Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA.

出版信息

Clin Breast Cancer. 2006 Dec;7(5):416-21. doi: 10.3816/CBC.2006.n.061.

DOI:10.3816/CBC.2006.n.061
PMID:17239269
Abstract
摘要

相似文献

1
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.NSABP B - 42：一项临床试验，旨在确定对于完成五年激素治疗（包括芳香化酶抑制剂（AI）或他莫昔芬，随后使用AI）的绝经后激素受体阳性乳腺癌患者，与安慰剂相比，来曲唑五年治疗在延长无病生存期方面的疗效。
Clin Breast Cancer. 2006 Dec;7(5):416-21. doi: 10.3816/CBC.2006.n.061.
2
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.来曲唑与他莫昔芬在绝经后早期乳腺癌女性中的比较。
N Engl J Med. 2005 Dec 29;353(26):2747-57. doi: 10.1056/NEJMoa052258.
3
Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.预防5年以上复发：MA.17延长辅助治疗试验
Semin Oncol. 2006 Apr;33(2 Suppl 7):S8-12. doi: 10.1053/j.seminoncol.2006.03.025.
4
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.降低绝经后女性他莫昔芬治疗结束后乳腺癌复发风险。
Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013.
5
Update of the BIG 1-98 Trial: where do we stand?BIG 1-98 试验更新：我们现在处于什么位置？
Breast. 2009 Oct;18 Suppl 3:S78-82. doi: 10.1016/S0960-9776(09)70278-4.
6
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.为激素敏感性乳腺癌绝经后女性选择早期辅助治疗：芳香化酶抑制剂与他莫昔芬的比较。
Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4.
7
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.来曲唑用于早期乳腺癌患者他莫昔芬治疗五年后的绝经后女性的一项随机试验。
N Engl J Med. 2003 Nov 6;349(19):1793-802. doi: 10.1056/NEJMoa032312. Epub 2003 Oct 9.
8
The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.早期辅助芳香化酶抑制剂治疗的应用：BIG 1-98来曲唑试验的贡献
Semin Oncol. 2006 Apr;33(2 Suppl 7):S2-7. doi: 10.1053/j.seminoncol.2006.03.026.
9
Overcoming recurrence risk: extended adjuvant endocrine therapy.克服复发风险：延长辅助内分泌治疗
Clin Breast Cancer. 2008 Dec;8(6):493-500. doi: 10.3816/CBC.2008.n.059.
10
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.来曲唑与他莫昔芬作为绝经后内分泌反应性早期乳腺癌女性初始辅助治疗的五年比较：BIG 1-98研究更新
J Clin Oncol. 2007 Feb 10;25(5):486-92. doi: 10.1200/JCO.2006.08.8617. Epub 2007 Jan 2.

引用本文的文献

1
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer.CDK4/6抑制剂的疗效与安全性：聚焦激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌
Drugs. 2025 Feb;85(2):149-169. doi: 10.1007/s40265-024-02144-y. Epub 2025 Jan 17.
2
Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting.CDK4/6 抑制剂对辅助治疗中芳香化酶抑制剂相关肌肉骨骼综合征（AIMSS）的影响。
Breast J. 2023 May 31;2023:3614296. doi: 10.1155/2023/3614296. eCollection 2023.
3
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.
开发一种预后工具，以指导绝经后早期乳腺癌患者延长辅助芳香化酶抑制剂使用时间至十年的决策。
Cancers (Basel). 2020 Dec 11;12(12):3725. doi: 10.3390/cancers12123725.
4
Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death.激素受体阳性乳腺癌的年轻患者有更高的乳腺癌特异性死亡长期风险。
J Breast Cancer. 2019 Mar;22(1):96-108. doi: 10.4048/jbc.2019.22.e13.
5
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.早期乳腺癌患者辅助内分泌治疗 10 年与 5 年的临床结局比较。
BMC Cancer. 2018 Oct 12;18(1):977. doi: 10.1186/s12885-018-4878-4.
6
Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.可手术乳腺癌初始治疗后5年以上复发的预测因素。
World J Surg Oncol. 2016 Aug 24;14(1):223. doi: 10.1186/s12957-016-0988-0.
7
The Globalization of Cooperative Groups.合作团体的全球化
Semin Oncol. 2015 Oct;42(5):693-712. doi: 10.1053/j.seminoncol.2015.07.003. Epub 2015 Jul 10.
8
Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.内分泌治疗依从性：一项关于影响治疗依从性和停药因素的横断面研究。
Ir J Med Sci. 2016 May;185(2):383-92. doi: 10.1007/s11845-015-1307-4. Epub 2015 May 14.
9
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.激素受体阳性早期乳腺癌辅助内分泌治疗疗效的更新评价。
Curr Oncol. 2009 Jul;16 Suppl 2(Suppl 2):S1-13. doi: 10.3747/co.v16i0.455.
10
Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.有效降低绝经后激素敏感性乳腺癌患者早期复发风险的治疗策略：芳香化酶抑制剂初始治疗与序贯治疗对比
J Cancer Res Clin Oncol. 2007 Dec;133(12):905-16. doi: 10.1007/s00432-007-0297-7. Epub 2007 Sep 6.